Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jincaopian is a botanical drug developed by Beijing Konruns Pharmaceutical for the treatment of chronic pelvic pain (CPP) following pelvic inflammatory disease (PID). Classified as a Class 1.2 innovative Chinese medicine, it is formulated as an oral tablet containing standardized plant extracts. The drug is designed to provide analgesic and anti-inflammatory effects, targeting the persistent pain and inflammatory environment characteristic of chronic pelvic conditions. Clinical development has progressed to Phase III trials, where Jincaopian is being evaluated for its efficacy in reducing pain intensity and improving the quality of life in women suffering from long-term pelvic pain following PID.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jincaopian.